OrthoSpace
OrthoSpace Ltd. (“OrthoSpace” or “the Company”) announced that it has surpassed the midway point for patient enrollment in its U.S. Investigational Device Exemption (IDE) pivotal study of the InSpace biodegradable balloon system for the treatment of massive rotator cuff tears.... more
OrthoSpace Ltd. (“OrthoSpace” or “the Company”) announced the publication of long-term follow-up data for patients enrolled in an open-label, single-arm, prospective study evaluating the use of the InSpace System for the treatment of massive rotator cuff tears (RCTs). The study,... more
OrthoSpace Ltd. ("OrthoSpace" or "Company") announced a publication in the December issue of Musculoskeletal Surgery citing positive results for their InSpace System in the surgical treatment of massive rotator cuff tears (MRCTs). Patients undergoing the InSpace procedure experienced durable improvements... more
CAESAREA, Israel, Dec. 1, 2016 OrthoSpace, Ltd., a global innovative shoulder implant company, today announces that it has closed on a $7 million equity financing round. The funds will be used to support the ongoing US Investigational Device Exemption (IDE)... more
OrthoSpace Ltd. announced the enrollment of the first three patients in its US Investigational Device Exemption (IDE) pivotal study. The study is a 184 patient randomized, single blinded control study that compares the Company's InSpace biodegradable balloon system to conventional... more
OrthoSpace Ltd. announced the completion of a financing transaction led by HealthpointCapital, LLC, which also includes existing investors Smith & Nephew and TriVentures. The proceeds from the transaction will facilitate the Company's continued market adoption, clinical study programs and entry... more
Complete Archive
